SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-037637
Filing Date
2024-03-28
Accepted
2024-03-28 08:00:48
Documents
90
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K cadl-20231231.htm   iXBRL 10-K 2715972
2 EX-10.19 cadl-ex10_19.htm EX-10.19 80400
3 EX-23.1 cadl-ex23_1.htm EX-23.1 2802
4 EX-31.1 cadl-ex31_1.htm EX-31.1 14048
5 EX-31.2 cadl-ex31_2.htm EX-31.2 14072
6 EX-32.1 cadl-ex32_1.htm EX-32.1 14234
7 EX-97.1 cadl-ex97_1.htm EX-97.1 47365
8 GRAPHIC img213000773_0.jpg GRAPHIC 64385
  Complete submission text file 0000950170-24-037637.txt   10108212

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20231231.xsd EX-101.SCH 1533917
94 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20231231_htm.xml XML 1306347
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40629 | Film No.: 24793609
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)